Bone

Member Access Processing (MAP) Taps Steve Bone as New CEO

Retrieved on: 
Wednesday, September 27, 2023
Bone, Pepperdine University, Neobank, FIS, Intelligence, First Entertainment Credit Union, Martini, History, Visa, ATM, Acquisition, OGO, As a service, Knowledge, MAP, Management, Online shopping, Bank

SEATTLE, Sept. 27, 2023 /PRNewswire-PRWeb/ -- Member Access Processing (MAP), the nation's leading provider of the Visa DPS Debit, Credit, ATM, Prepaid, and Mobile Processing platform to credit unions, announced today that Steve Bone has accepted a position as the company's new chief executive officer. Bone has been an executive in financial services technology for 31 years and he brings deep technology experience to his new position at MAP. Most recently, he served as chief operations officer at Trellance, which provides data analytics and business intelligence solutions to the credit union industry.

Key Points: 
  • SEATTLE, Sept. 27, 2023 /PRNewswire-PRWeb/ -- Member Access Processing ( MAP ), the nation's leading provider of the Visa DPS Debit, Credit, ATM, Prepaid, and Mobile Processing platform to credit unions, announced today that Steve Bone has accepted a position as the company's new chief executive officer.
  • "The board believes Steve has the knowledge and skills to move Member Access Processing into a future where technology plays a vital role in giving members better access to financial services with the strongest possible security," said Gordon Howe, chair of the board for MAP.
  • "I'm thrilled to join a company with an unrivaled reputation in the industry," said Bone, CEO of MAP.
  • For more information about Member Access Processing, please visit https://maprocessing.com/ .

The Fabletics and Khloé Kardashian Second Edit Celebrates the Bliss of Conquering Goals with New Fashion-Forward Pieces

Retrieved on: 
Tuesday, September 26, 2023
Online, Dark, Bone, VIP, Collection, Partnership, Life, Contour set, Edit, XXS, Leggings, Water, Aesthetics, Motivation, Growth, System, Principal, Perspiration, News, Fashion design, Retail, Design, Nightclub, Furniture, Merlot, Fabletics

EL SEGUNDO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Fabletics, the world’s most fashionable, high-performance active wear brand, announces the upcoming release of its second product partnership with entrepreneur, fitness lover and television star Khloé Kardashian. The latest nine-piece delivery is an expansion of “The Khloé Edit” and boasts a refined assortment of versatile, sculpted pieces meant for daily utility with an evolved color palette of high-shine and seasonal tones.

Key Points: 
  • The collection emulates the tranquility of water and embodies Kardashian’s personal passion for conquering and celebrating goals that fuel more growth – both mentally and physically.
  • “Bringing this collection to life has been a dream, because moving my body is a way that I prioritize both my mental and physical health,” said Kardashian.
  • “We are thrilled with the overwhelmingly positive response received from our first Edit with Khloé.
  • Fabletics x Khloé will be available in Fabletics physical stores across the globe and for purchase at www.Fabletics.com/Khloe starting Saturday, September 30, 2023.

SONEX HEALTH HOSTS FIRST-EVER FORUM FOR SURGEONS TO EXPLORE AND SHAPE THE FUTURE OF MSK ULTRASOUND IN HAND SURGERY

Retrieved on: 
Tuesday, September 26, 2023
GE HealthCare, Bone, Surgeon, University, University of Pittsburgh School of Dental Medicine, Education, Thomas Jefferson University, Health, GE, Research, ASSH, Sonex Aircraft, Konica Minolta, Integration, Westin Harbour Castle Hotel, Physician, Clarius, Orthopedic surgery, MSK, Human musculoskeletal system, Portable ultrasound, Society, Medical device

EAGAN, Minn., Sept. 26, 2023 /PRNewswire/ -- Sonex Health and the Institute of Advanced Ultrasound Guided Procedures have announced they are hosting the first annual Musculoskeletal (MSK) Ultrasound Forum, bringing surgeons together to exchange ideas, engage in hands-on learning activities, and shape the future of MSK ultrasound in hand surgery. This first-ever forum on Oct. 3 from 4 to 10 p.m. at the Westin Harbour Castle precedes the American Society for Surgery of the Hand (ASSH) 2023 Annual Meeting in Toronto Oct. 5-7.

Key Points: 
  • EAGAN, Minn., Sept. 26, 2023 /PRNewswire/ -- Sonex Health and the Institute of Advanced Ultrasound Guided Procedures have announced they are hosting the first annual Musculoskeletal (MSK) Ultrasound Forum, bringing surgeons together to exchange ideas, engage in hands-on learning activities, and shape the future of MSK ultrasound in hand surgery.
  • "We're excited to bring together thought leaders to educate, discuss and explore the future of MSK ultrasound in this first event of its kind," said Dr. John R. Fowler, MSK Ultrasound Forum event chair, associate professor and assistant dean for medical student research, University of Pittsburgh's Department of Orthopaedic Surgery.
  • "Partnering with Sonex Health and a renowned executive committee of physicians, this annual meeting focuses on innovation, and we welcome surgeons to join us in physician-led discussions, education and exchange of ideas in shaping the future of MSK ultrasound."
  • The forum brings together more than 75 hand surgeons to advance MSK ultrasound through innovation, education and training.

Mesentech Doses First Patients with Investigational Drug MES1022 to Accelerate Healing of Bone Fractures

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Health, Clinical Trials, Medicinal chemistry, Bone cancer in cats and dogs, Surgeon, Therapy, Drug discovery, Head, Osteosarcoma, Bone, Research, Merck & Co., Factorization of polynomials, Prostaglandin, Former, Metastasis, New York Blood Center, Patient, CBO, Chronic kidney disease-mineral and bone disorder, Chief financial officer, Merck, EP4, Elective surgery, Safety, Pharmaceutical industry, Medical imaging, Dentistry

Efficient drug delivery into bones remains a barrier in developing treatments for diseases of bone.

Key Points: 
  • Efficient drug delivery into bones remains a barrier in developing treatments for diseases of bone.
  • The bone is a complex, dynamic tissue with unique properties that make it a formidable challenge for drug efficient penetration.
  • The company successfully dosed the first patients via subcutaneous injection in a Phase 1 study evaluating MES1022, a bone-selective EP4 receptor agonist prodrug they are developing for bone regeneration, with the first application for accelerating healing of bone fractures.
  • “MES1022 is well-positioned to be the first therapy that mimics and enhances the natural processes the body uses to stimulate bone repair and healing.

Collaboration Between Viral Nation's Original Programming Division and Buck Productions Unleashes a Creative Powerhouse for Talent-Driven Content

Retrieved on: 
Thursday, September 21, 2023
Online, Sports, Entertainment, Social Media, Search Engine Marketing, Influencer, General Entertainment, Digital Marketing, TV and Radio, Marketing, Content Marketing, Communications, Basketball, SLAM, Bone, MTV, Partnership, Reelz, Don't Panic (All Time Low album), Buck, The Bone Collector, Attention, Complex Networks, Sale, Chemistry, Seven Bucks Productions, Larry Williams (basketball), CBC, NBA, Television, Originality, Harlem, Red Bull, HGTV, Social media, Software, Video game, Nightclub, Serotonin

This partnership allows Buck to develop unparalleled original programming featuring Viral Nation's renowned social media talent.

Key Points: 
  • This partnership allows Buck to develop unparalleled original programming featuring Viral Nation's renowned social media talent.
  • "We can’t wait to link up with Viral Nation and Buck Productions for this exciting, new original program series,” said Hemmings, founding member of Basement Gang.
  • "This partnership marks yet another tremendous milestone for Viral Nation's Original Programming division," said Paul Telner, head of Programming for Viral Nation_Talent, who has co-developed multiple projects with Buck Productions previously.
  • "I'm excited to partner with Viral Nation and Buck Productions to showcase my journey,” said Williams.

Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

Retrieved on: 
Monday, September 18, 2023
Human, AL, Osteopetrosis, University, RNA, Bone disease, Autosome, Nucleic acid, Messenger, Small RNA, University of L'Aquila, Bone, House, American Society for Bone and Mineral Research, Patient, Annual general meeting, Mouse, Silicon, LNP (newspaper), FDA, Phenotype, IND, Society, Safety, Pharmaceutical industry, Medical imaging, Vaccine

These results could have significant translational impact on bone disease therapies and open the path to human trials of SiSaf’s potentially curative treatment for Osteopetrosis ADO2.

Key Points: 
  • These results could have significant translational impact on bone disease therapies and open the path to human trials of SiSaf’s potentially curative treatment for Osteopetrosis ADO2.
  • There are currently no approved treatments for this debilitating disease and no other treatments currently in clinical trials.
  • SIS-101-ADO, SiSaf’s lead in house program, is an ADO2-specific siRNA specifically designed against the human CLCN7G215R mRNA formulated with the company’s sshLNP.
  • In addition, due to the serious manifestations of this rare skeletal disorder in children, the FDA granted SIS-101-ADO Rare Pediatric Disease Designation for the treatment of Autosomal Dominant Osteopetrosis.

Global Musculoskeletal Disorders Drugs Market to Surge, Projected to Reach $109.4 Billion by 2029 with 4.2% CAGR - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 13, 2023
Health, Pharmaceutical, Online, Osteoarthritis, Prevalence, Route of administration, Arena Pharmaceuticals, Arthritis, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Analgesic, COVID-19, Distribution (marketing), Ageing, Microsoft, Bone, DSM-IV codes, MicroRNA, Life expectancy, Musculoskeletal disorder, Hospital, Arthropathy, Market, Administration, Back pain, Disease-modifying antirheumatic drug, Compound annual growth rate, UCB, Acquisition, AbbVie, Eli Lilly and Company, Pharmacy, Human musculoskeletal system, Growth, Johnson & Johnson, Immunology, Merck & Co., Novartis, Pharmaceutical industry, Agriculture, Pfizer

The global Musculoskeletal Disorders Drugs Market is set to witness significant expansion, projected to reach a substantial value of $109.4 billion by 2029, with a steady Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period.

Key Points: 
  • The global Musculoskeletal Disorders Drugs Market is set to witness significant expansion, projected to reach a substantial value of $109.4 billion by 2029, with a steady Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period.
  • The rise in life expectancy and aging population leads to a surge in musculoskeletal diseases, boosting the demand for treatments and subsequently propelling market expansion.
  • High Prevalence of Musculoskeletal Diseases: Over 150 diseases and conditions fall under the category of musculoskeletal disorders, affecting individuals globally.
  • The prevalence of these disorders, such as arthritis, osteoarthritis, and back pain, drives the demand for drugs and treatment options.

Actio Biosciences Announces $55 Million Series A Financing to Advance Precision Medicine Approach for Rare and Common Diseases

Retrieved on: 
Tuesday, September 12, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, EcoRI, Partnership, Probability, Therapy, Vocal cord paresis, Atlas, Biomedical Research, Bone, Jackson Laboratory, Translation, Chemistry, Muscle weakness, Patient, Medicine, JAX, Drug discovery, Biology, Rare, Gene, TRPV4, Disease, Pharmaceutical industry, Vaccine, Management, Pronuntiatio

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the completion of a $55 million Series A financing.

Key Points: 
  • Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the completion of a $55 million Series A financing.
  • The financing was led by Canaan and DROIA Ventures, with participation from existing investors Deerfield Management and EcoR1, as well as new investor Euclidean Capital.
  • The company’s platform comprises a vast proprietary target database, called the Rare Disease Target Atlas, and unparalleled expertise in bioinformatics, biology and chemistry.
  • Actio’s pipeline is led by a program targeting TRPV4, an ion channel target identified as high-value through the company’s platform.

Inside information: Bioretec enters into the U.S. distribution agreement with Spartan Medical for the RemeOs™ screws

Retrieved on: 
Tuesday, September 12, 2023
Partnership, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, Defense, Health care, Veterans Health Administration, Coronavirus Scientific Advisory Board, Bone, School, Patient, United States Department of Veterans Affairs, Government, FDA, Trauma, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Medical device, Pharmaceutical industry

The signed distribution agreement signals the commencement of the rollout of the RemeOs™ screws in the United States, the world's largest orthopedic market.

Key Points: 
  • The signed distribution agreement signals the commencement of the rollout of the RemeOs™ screws in the United States, the world's largest orthopedic market.
  • The agreement outlines the initiation of a controlled launch of the U.S. distribution of the RemeOsTM screws within strategically selected top-tier academic centers.
  • Additionally, the distribution agreement involves a potential to penetrate into the extensive U.S. Department of Defense and the Veterans Administration healthcare market.
  • "When clinicians are seeking innovative, best-in-class medical technologies, I'm proud to say they come to us," says Vince Proffitt, President of Spartan Medical.

Inside information: Bioretec enters into the U.S. distribution agreement with Spartan Medical for the RemeOs™ screws

Retrieved on: 
Tuesday, September 12, 2023
Partnership, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, Defense, Health care, Veterans Health Administration, Coronavirus Scientific Advisory Board, Bone, School, Patient, United States Department of Veterans Affairs, Government, FDA, Trauma, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Medical device, Pharmaceutical industry

The signed distribution agreement signals the commencement of the rollout of the RemeOs™ screws in the United States, the world's largest orthopedic market.

Key Points: 
  • The signed distribution agreement signals the commencement of the rollout of the RemeOs™ screws in the United States, the world's largest orthopedic market.
  • The agreement outlines the initiation of a controlled launch of the U.S. distribution of the RemeOsTM screws within strategically selected top-tier academic centers.
  • Additionally, the distribution agreement involves a potential to penetrate into the extensive U.S. Department of Defense and the Veterans Administration healthcare market.
  • "When clinicians are seeking innovative, best-in-class medical technologies, I'm proud to say they come to us," says Vince Proffitt, President of Spartan Medical.